Cargando…

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

PURPOSE: This study aimed to characterize the prescribing of dalfampridine extended release (D-ER) 10 mg tablet treatment in people with multiple sclerosis (MS). METHODS: A retrospective cohort study was performed using Medco pharmacy and medical claims. Medical claims were used to identify MS patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jara, Michele, Sidovar, Matthew F, Henney, Herbert R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274131/ https://www.ncbi.nlm.nih.gov/pubmed/25565851 http://dx.doi.org/10.2147/TCRM.S75837

Ejemplares similares

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis
por: Guo, Amy, et al.
Publicado: (2016)

Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study
por: Samara, Emil, et al.
Publicado: (2014)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
por: Schwartz, Kateryna, et al.
Publicado: (2017)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
por: Goodman, Andrew D, et al.
Publicado: (2015)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke
por: Page, Stephen J., et al.
Publicado: (2020)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
por: Okuda, Darin T, et al.
Publicado: (2022)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
por: Okuda, Darin T, et al.
Publicado: (2023)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Metoprolol succinate extended release/hydrochlorothiazide combination tablets
por: Hainer, James W, et al.
Publicado: (2007)

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
por: Zaman, Rameez, et al.
Publicado: (2022)

Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
por: Malamud, Emily, et al.
Publicado: (2022)

Useful Extend-release Chitosan Tablets with High Antioxidant Activity
por: Yasufuku, Taira, et al.
Publicado: (2010)

Development and bioequivalence study of potassium chloride extended release tablets
por: Le Thi, Thu Van, et al.
Publicado: (2018)

Agreement between self-reported morbidity and pharmacy claims data for prescribed medications in an older community based population
por: Mannion, Clionadh, et al.
Publicado: (2020)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data
por: Carroll, Cathryn A, et al.
Publicado: (2014)

Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
por: Oliveira, Paulo Renato, et al.
Publicado: (2013)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not
por: Chang, Hsien-Yen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k6ml4tq8crmar5637m95jq9cia